Literature DB >> 27888958

Improving Metabolic Syndrome Screening on Patients on Second Generation Antipsychotic Medication.

Esther Kioko1, Kimberly Williams2, Beth Newhouse3.   

Abstract

AIM: This quality improvement project aims at stressing the importance of screening for metabolic syndrome (MS) on patients with serious mental illness (SMI) managed with second generation antipsychotic (SGA) medication.
METHOD: One hundred charts of patients who were on SGA (n=100) were randomly selected from more than 1000 charts for the purpose of this project with (n=50) charts for pre-intervention and (n=50) charts for post intervention. A chi-square test of independence was calculated comparing the frequency of labs and vital done in pre-intervention and post-intervention period.
RESULTS: A significant interaction was found [χ2(2)=32.67, p<.001] indicating that providers were more likely to order labs in postintervention (62%) than in pre-intervention (22%). No significant relationship was found for vital signs [χ2(1)=.542, p>.05]. The use of the screening and monitoring tool showed that gaps exist in the screening for MS among patients on SGA. IMPLICATION TO PRACTICE: Advanced health nurse practitioners are well placed to take the lead in screening, monitoring, and implementing the necessary measures to address MS among patients with serious mental illness. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27888958     DOI: 10.1016/j.apnu.2016.03.004

Source DB:  PubMed          Journal:  Arch Psychiatr Nurs        ISSN: 0883-9417            Impact factor:   2.218


  1 in total

Review 1.  Interventions to increase access to or uptake of physical health screening in people with severe mental illness: a realist review.

Authors:  Frédérique Lamontagne-Godwin; Caroline Burgess; Sarah Clement; Melanie Gasston-Hales; Carolynn Greene; Anne Manyande; Deborah Taylor; Paul Walters; Elizabeth Barley
Journal:  BMJ Open       Date:  2018-02-10       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.